These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7731677)

  • 21. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
    Lin J; Chen J; Elenbaas B; Levine AJ
    Genes Dev; 1994 May; 8(10):1235-46. PubMed ID: 7926727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
    Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.
    Martin K; Trouche D; Hagemeier C; Sørensen TS; La Thangue NB; Kouzarides T
    Nature; 1995 Jun; 375(6533):691-4. PubMed ID: 7791903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
    Chen X; Lu W
    Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA-binding and transactivation activities are essential for TAp63 protein degradation.
    Ying H; Chang DL; Zheng H; McKeon F; Xiao ZX
    Mol Cell Biol; 2005 Jul; 25(14):6154-64. PubMed ID: 15988026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of DNA binding of p53 by its C-terminal domain.
    Weinberg RL; Freund SM; Veprintsev DB; Bycroft M; Fersht AR
    J Mol Biol; 2004 Sep; 342(3):801-11. PubMed ID: 15342238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain.
    Finlan L; Hupp TR
    J Biol Chem; 2004 Nov; 279(47):49395-405. PubMed ID: 15337767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The C terminus of p53 binds the N-terminal domain of MDM2.
    Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
    Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of Mdm2-directed degradation by the C terminus of p53.
    Kubbutat MH; Ludwig RL; Ashcroft M; Vousden KH
    Mol Cell Biol; 1998 Oct; 18(10):5690-8. PubMed ID: 9742086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability.
    Dolezelova P; Cetkovska K; Vousden KH; Uldrijan S
    FEBS Lett; 2012 Jul; 586(16):2225-31. PubMed ID: 22659184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
    Haupt Y; Barak Y; Oren M
    EMBO J; 1996 Apr; 15(7):1596-606. PubMed ID: 8612583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
    Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
    Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.
    Mendrysa SM; McElwee MK; Michalowski J; O'Leary KA; Young KM; Perry ME
    Mol Cell Biol; 2003 Jan; 23(2):462-72. PubMed ID: 12509446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical and functional interaction between wild-type p53 and mdm2 proteins.
    Haines DS; Landers JE; Engle LJ; George DL
    Mol Cell Biol; 1994 Feb; 14(2):1171-8. PubMed ID: 8289798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
    Unger T; Mietz JA; Scheffner M; Yee CL; Howley PM
    Mol Cell Biol; 1993 Sep; 13(9):5186-94. PubMed ID: 8355677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.
    Picksley SM; Vojtesek B; Sparks A; Lane DP
    Oncogene; 1994 Sep; 9(9):2523-9. PubMed ID: 8058315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.